Logistics services provider Blue Dart on Tuesday said it will offer a complete supply chain solution for the life sciences and clinical trials sector and reefer vehicles (cold chain) services, to ensure seamless transport of shipments like vaccines.
The firm, which is a part of the Deutsche Post DHL Group (DPDHL), has capability to handle various temperature requirements.
As the development of the COVID-19 vaccine leapfrogs across development phases, stringent temperature requirements (up to - 80C) will be a critical factor for its transportation and warehousing at every stage, Blue Dart said in a release.
Stating that an efficient and specialized logistics network will be a prerequisite, to ensure safe and rapid delivery of billions of COVID-19 vaccine doses for mass immunization, and other temperature sensitive pharma products on a national and global scale, the company said, "It is ramping up its infrastructure with its pre-existing specialised Temperature Controlled Logistics (TCL) to combat the pandemic".
The company said it has successfully tailored its existing TCL solution to transport critical shipments such as vaccines, medical samples and more, adding that its TCL teams work with three industry specific segments--clinical research organisation, vaccine/testing kit manufacturers and active pharma Ingredient for delivery of shipments.
"The right partnerships are vital to secure critical medical supplies during health emergencies. We are actively working with various pharmaceutical organizations that are conducting clinical trials to produce a COVID-19 vaccine in India in their pre and post production journey," said Ketan Kulkarni CMO & Head Business Development, Blue Dart.
With an agile response team overseeing the upscaling of the current capabilities, strong fleet of dedicated Boeing 757 aircraft and robust infrastructure for TCL solutions, Blue Dart is capable and prepared to meet any immediate large-scale demand, he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)